- Home
- PCLA vs TPST Comparison
PCLA vs TPST Comparison
Compare PCLA & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCLA
- TPST
- Stock Information
- Founded
- PCLA 2008
- TPST 2011
- Country
- PCLA Japan
- TPST United States
- Employees
- PCLA N/A
- TPST N/A
- Industry
- PCLA Building Products
- TPST Biotechnology: Pharmaceutical Preparations
- Sector
- PCLA Consumer Discretionary
- TPST Health Care
- Exchange
- PCLA Nasdaq
- TPST Nasdaq
- Market Cap
- PCLA 71.3M
- TPST 33.0M
- IPO Year
- PCLA 2025
- TPST N/A
- Fundamental
- Price
- PCLA $0.49
- TPST $7.54
- Analyst Decision
- PCLA
- TPST Hold
- Analyst Count
- PCLA 0
- TPST 3
- Target Price
- PCLA N/A
- TPST $30.00
- AVG Volume (30 Days)
- PCLA 3.9M
- TPST 94.0K
- Earning Date
- PCLA 01-01-0001
- TPST 08-11-2025
- Dividend Yield
- PCLA N/A
- TPST N/A
- EPS Growth
- PCLA N/A
- TPST N/A
- EPS
- PCLA N/A
- TPST N/A
- Revenue
- PCLA $5,475,228.00
- TPST N/A
- Revenue This Year
- PCLA N/A
- TPST N/A
- Revenue Next Year
- PCLA N/A
- TPST N/A
- P/E Ratio
- PCLA N/A
- TPST N/A
- Revenue Growth
- PCLA 40.19
- TPST N/A
- 52 Week Low
- PCLA $0.37
- TPST $5.35
- 52 Week High
- PCLA $9.80
- TPST $28.34
- Technical
- Relative Strength Index (RSI)
- PCLA N/A
- TPST 56.78
- Support Level
- PCLA N/A
- TPST $7.13
- Resistance Level
- PCLA N/A
- TPST $8.75
- Average True Range (ATR)
- PCLA 0.00
- TPST 0.47
- MACD
- PCLA 0.00
- TPST 0.12
- Stochastic Oscillator
- PCLA 0.00
- TPST 54.17
About PCLA PicoCELA Inc. American Depositary Shares
PicoCELA Inc specializes in manufacturing, installing, and servicing enterprise wireless mesh solutions. The company generates revenue from two main sources: product equipment sales, and Software as a Service (SaaS) and maintenance services. The company develops the PCWL series of mesh Wi-Fi access points, which utilize its proprietary PicoCELA Backhaul Engine (PBE) technology to enable wireless communication. The company outsources manufacturing and sells these devices directly to customers through distributors. Additionally, the company offers a cloud portal service in a SaaS model, allowing users to monitor connectivity and traffic at their access points. This platform also supports the installation of proprietary edge-computing software into the devices.
About TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.